russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2017-8-114-121russjcardiol-2543Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERФАРМАКОЛОГИЧЕСКОЕ ПРЕКОНДИЦИОНИРОВАНИЕ. В ФОКУСЕ — НИКОРАНДИЛPHARMACOLOGICAL PRECONDITIONING. FOCUS ON NICORANDILГостищевР. В.GostishchevR. V.

аспирант отдела рентгенэндоваскулярных методов диагностики и лечения ИКК им. А. Л. Мясникова

gostiroman@gmail.comСоболеваГ. Н.SobolevaG. N.

д. м.н., в. н.с. отдела ангиологии ИКК им. А. Л. Мясникова

СамкоА. Н.SamkoA. N.

профессор, д. м.н., руководитель отдела рентгенэндоваскулярных  методов диагностики и лечения ИКК им. А. Л. Мясникова

ОсиевА. Г.OsievA. G.

профессор, д. м.н., руководитель отделения хирургии сердца и сосудов

ФГБУ Национальный исследовательский медицинский центр кардиологии Минздрава РоссииРоссияNational Medical Research Center for CardiologyRussian FederationГБУЗ МО Московский областной научно-исследовательский клинический институт им. М. Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical Institute (MONIKI)Russian Federation20170710201708114121Copyright © Гостищев Р.В., Соболева Г.Н., Самко А.Н., Осиев А.Г., 20172017Гостищев Р.В., Соболева Г.Н., Самко А.Н., Осиев А.Г.Gostishchev R.V., Soboleva G.N., Samko A.N., Osiev A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2543

В данном литературном обзоре представлена сводная информации о феномене кондиционирования и, в частности, фармакологического прекондиционирования миокарда. Широко представлена информация об активаторе АТФ-зависимых калиевых каналов — никорандиле. Обсуждаются механизм действия, показатели эффективности и безопасности препарата. Приведенные данные свидетельствуют о том, что на современном этапе никорандил не является обязательным препаратом для сопровождения чрескожного коронарного вмешательства, однако данные клинических исследований, подтверждают возможность уменьшения риска развития перипроцедурного повреждения миокарда при условии превентивного назначения этого препарата. Представлены данные о позитивном влиянии никорандила на сократительную функцию миокарда и клинические исходы.

The review focuses on the gathered data related to preconditioning phenomenon and, particularly, pharmacological preconditioning of myocardium. The information presented, on the activator of ATP-dependent potassium channels nicorandil. Mechanism of action is discussed, as efficacy and safety data. The evidence shows that, recently, nicorandil is not an obligatory medication to follow percutaneous intervention on coronary arteries, though clinical trials data confirm the possibility of periprocedural myocardium damage risk reduction, if the drug is prescribed in advance. The data presented, on positive influence of nicorandil on myocardial contractility and clinical outcomes.

фармакологическое прекондиционирование миокарданикорандилактиватор АТФ-зависимых калиевых каналовчрескожные коронарные вмешательствакардиоферментыpharmacological preconditioning of myocardiumnicorandilactivator of ATP-dependent potassium channelspercutaneous coronary interventionscardiac enzymesReferencesThe rubricator of clinical recommendations and related documents [Electronic resource] Russian Society of Cardiologists; National Society of Atherosclerosis; National Society for Atherothrombosis — Electron. Data. M.: Clinical recommendations. Stable coronary heart disease — Access mode: http://cr.rosminzdrav.ru/schema.html?id=133#/text, free. Ver. From the screen (date of circulation 10.04.2017). Russian (Рубрикатор клинических рекомендаций и связанных документов [Электронный ресурс] Российское кардиологическое общество; Национальное общество по изучению атеросклероза; Национальное общество по атеротромбозу — Электрон. дан. М.: Клинические рекомендации. Стабильная ишемическая болезнь сердца Режим доступа: http://cr.rosminzdrav.ru/schema.html?id=133#/text, свободный. Загл. с экрана (дата обращения 10.04.2017).The rubricator of clinical recommendations and related documents [Electronic resource] Russian Society of Cardiologists; National Society of Atherosclerosis; National Society for Atherothrombosis — Electron. Data. M.: Clinical recommendations. Stable coronary heart disease — Access mode: http://cr.rosminzdrav.ru/schema.html?id=133#/text, free. Ver. From the screen (date of circulation 10.04.2017). Russian (Рубрикатор клинических рекомендаций и связанных документов [Электронный ресурс] Российское кардиологическое общество; Национальное общество по изучению атеросклероза; Национальное общество по атеротромбозу — Электрон. дан. М.: Клинические рекомендации. Стабильная ишемическая болезнь сердца Режим доступа: http://cr.rosminzdrav.ru/schema.html?id=133#/text, свободный. Загл. с экрана (дата обращения 10.04.2017).Fraker Jr TD, Fihn SD. 2002 Chronic Stable Angina Writing Committee, American College of Cardiology, American Heart Association. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007 Dec 4; 50 (23): 2264-746.Fraker Jr TD, Fihn SD. 2002 Chronic Stable Angina Writing Committee, American College of Cardiology, American Heart Association. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007 Dec 4; 50 (23): 2264-746.Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006 Jun; 27 (11): 1341-81.Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006 Jun; 27 (11): 1341-81.Horinaka S . Use of Nicorandil in Cardiovascular Disease and Its Optimization.Drugs;2011, 71, 9:1105.Horinaka S . Use of Nicorandil in Cardiovascular Disease and Its Optimization.Drugs;2011, 71, 9:1105.Nallamothu BK, Chetcuti S, Mukherjee D, et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol. 2003; 91:1272-4.Nallamothu BK, Chetcuti S, Mukherjee D, et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol. 2003; 91:1272-4.Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18-23Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18-23Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-103term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-8.Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-103term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-8.Novack V, Pencina M, Cohen DJ, et al. Troponin criteria for myocardial infarction after percuta-neous coronary intervention. Arch. Intern. Med. 2012; 172: 502-8.Novack V, Pencina M, Cohen DJ, et al. Troponin criteria for myocardial infarction after percuta-neous coronary intervention. Arch. Intern. Med. 2012; 172: 502-8.Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv 2010; 3:602-10.Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv 2010; 3:602-10.Cavallini C, Verdecchia P, Savonitto S, et al. Italian Atherosclerosis, Thrombosis and Vascular Biology and Society for Invasive Cardiology–GISE Investigators Prognostic value of isolated troponin I elevation after percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3:431-5.Cavallini C, Verdecchia P, Savonitto S, et al. Italian Atherosclerosis, Thrombosis and Vascular Biology and Society for Invasive Cardiology–GISE Investigators Prognostic value of isolated troponin I elevation after percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3:431-5.Prasad A Jr, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes following percutaneous coronary intervention. Circ Cardiovasc Intervent 2008;1:10-9.Prasad A Jr, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes following percutaneous coronary intervention. Circ Cardiovasc Intervent 2008;1:10-9.Thygesen K, Alpert J, Jaffe A, et al. Third universal definition of myocardial infarction. European Heart Journal (2012) 33, 2551-67.Thygesen K, Alpert J, Jaffe A, et al. Third universal definition of myocardial infarction. European Heart Journal (2012) 33, 2551-67.Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077-82.Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077-82.Mironova O. Yu. The clinical and prognostic value of miocardium infarction, caused by estimated coronary angioplasty in patients with stable coronary heart disease: the dissertation ... ThePhD: 14.01.05., 14.01.13. Moscow, 2015, 114с Russian (Миронова О. Ю. Клиническое и прогностическое значение инфаркта миокарда, развившегося в результате проведения плановой коронарной ангиопластики у пациентов со стабильной ишемической болезнью сердца: диссертация … кандидата медицинских наук: 14.01.05., 14.01.13. Москва, 2015,114с).Mironova O. Yu. The clinical and prognostic value of miocardium infarction, caused by estimated coronary angioplasty in patients with stable coronary heart disease: the dissertation ... ThePhD: 14.01.05., 14.01.13. Moscow, 2015, 114с Russian (Миронова О. Ю. Клиническое и прогностическое значение инфаркта миокарда, развившегося в результате проведения плановой коронарной ангиопластики у пациентов со стабильной ишемической болезнью сердца: диссертация … кандидата медицинских наук: 14.01.05., 14.01.13. Москва, 2015,114с).Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-11.Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-11.Akinina SA Comparative prognostic value of creatine phosphokinase MB fraction and troponin T in the diagnosis of periprocedural myocardial damage. Russian Cardiology Journal 2012, 3(95): 19- 24 Russian (Акинина С. А. Сравнительное прогностическое значение креатинфосфокиназы МВ- фракции и тропонина Т при диагностике перипроцедурного повреждения миокарда. Российский кардиологический журнал 2012, 3(95): 19-24).Akinina SA Comparative prognostic value of creatine phosphokinase MB fraction and troponin T in the diagnosis of periprocedural myocardial damage. Russian Cardiology Journal 2012, 3(95): 19- 24 Russian (Акинина С. А. Сравнительное прогностическое значение креатинфосфокиназы МВ- фракции и тропонина Т при диагностике перипроцедурного повреждения миокарда. Российский кардиологический журнал 2012, 3(95): 19-24).Bokeria LA, Alekyan BG. The state of x-ray endovascular diagnosis and treatment of the heart and vascular diseases in the Russian Federation (2015) Russian (Бокерия Л. А., Алекян Б. Г. Состояние рентгенэндоваскулярной диагностики и лечения заболеваний сердца и сосудов в Российской Федерации (2015 г).Bokeria LA, Alekyan BG. The state of x-ray endovascular diagnosis and treatment of the heart and vascular diseases in the Russian Federation (2015) Russian (Бокерия Л. А., Алекян Б. Г. Состояние рентгенэндоваскулярной диагностики и лечения заболеваний сердца и сосудов в Российской Федерации (2015 г).Murry CE, Jenning RD, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74 (5): 1122-36.Murry CE, Jenning RD, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74 (5): 1122-36.Turer AT, Hill JA. Pathogenesis of myocardial ischemia- reperfusion injury and rationale for therapy. Am J Cardiol 2010; 106: 360-8.Turer AT, Hill JA. Pathogenesis of myocardial ischemia- reperfusion injury and rationale for therapy. Am J Cardiol 2010; 106: 360-8.Kharbanda RK. Cardiac conditioning: a review of evolving strategies to reduce ischemiareperfusion injury. Heart 2010; 96: 1179-86.Kharbanda RK. Cardiac conditioning: a review of evolving strategies to reduce ischemiareperfusion injury. Heart 2010; 96: 1179-86.Hausenloy DJ, YellonDM. Preconditioning and postconditioning: underlying and clinical application. Atherosclerosis 2009; 204 (2): 334-41.Hausenloy DJ, YellonDM. Preconditioning and postconditioning: underlying and clinical application. Atherosclerosis 2009; 204 (2): 334-41.Lupanov VP, Maksimenko AV. Protective ischemia in cardiology. The forms of myocardium conditioning. Cardiovascular Therapy and Prevention, 2011; 10 (1): 96-103. Russian (Лупанов В. П., Максименко А. В. Протективная ишемия в кардиологии. Формы кондиционирования миокарда. Кардиоваскулярная терапия и профилактика, 2011;10(1): 96-103).Lupanov VP, Maksimenko AV. Protective ischemia in cardiology. The forms of myocardium conditioning. Cardiovascular Therapy and Prevention, 2011; 10 (1): 96-103. Russian (Лупанов В. П., Максименко А. В. Протективная ишемия в кардиологии. Формы кондиционирования миокарда. Кардиоваскулярная терапия и профилактика, 2011;10(1): 96-103).Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009; 104 (2): 189-202.Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009; 104 (2): 189-202.Boytsov SA. The pathogenesis of the chronic form of coronary heart disease. In the book. “Atherosclerosis and Coronary Heart Disease Manual” (edited by Chazov EI) Moscow “Media Medica” 2007; 330-48. Russian (Бойцов С. А. Патогенез хронической формы ишемической болезни сердца. В кн. “Руководство по атеросклерозу и ишемической болезни сердца’’ (под ред. акад. Е. И. Чазова) Москва “Медиа Медика” 2007; 330-48).Boytsov SA. The pathogenesis of the chronic form of coronary heart disease. In the book. “Atherosclerosis and Coronary Heart Disease Manual” (edited by Chazov EI) Moscow “Media Medica” 2007; 330-48. Russian (Бойцов С. А. Патогенез хронической формы ишемической болезни сердца. В кн. “Руководство по атеросклерозу и ишемической болезни сердца’’ (под ред. акад. Е. И. Чазова) Москва “Медиа Медика” 2007; 330-48).Lomivorotov VV, Ponomarev DN, Shmyrev VA, et al. The application of the remote ischemic preconditioning in cardiosurgical patients. General Intensive care. 2011; 7 (3): 63-9 Russian (Ломиворотов В. В., Пономарев Д. Н., Шмырев В. А. и др. Применение дистанционного ишемического прекондиционирования у кардиохирургических больных. Общая реаниматология. 2011; 7 (3): 63-9).Lomivorotov VV, Ponomarev DN, Shmyrev VA, et al. The application of the remote ischemic preconditioning in cardiosurgical patients. General Intensive care. 2011; 7 (3): 63-9 Russian (Ломиворотов В. В., Пономарев Д. Н., Шмырев В. А. и др. Применение дистанционного ишемического прекондиционирования у кардиохирургических больных. Общая реаниматология. 2011; 7 (3): 63-9).Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893-9.Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893-9.Sergienko VI, Petrosyan EA, Onopriyev VI, et al. The morphological lungs changes in the modeling and treatment of ischemic and reperfusion injuries of the limb. General Intensive care 2006; II (5-6): 129-32. Russian (Сергиенко В. И., Петросян Э. А., Оноприев В. И. и др. Морфологические изменения лёгких при моделировании и лечении ишемических и реперфузионных повреждений конечности. Общая реаниматология 2006; II (5-6): 129-32).Sergienko VI, Petrosyan EA, Onopriyev VI, et al. The morphological lungs changes in the modeling and treatment of ischemic and reperfusion injuries of the limb. General Intensive care 2006; II (5-6): 129-32. Russian (Сергиенко В. И., Петросян Э. А., Оноприев В. И. и др. Морфологические изменения лёгких при моделировании и лечении ишемических и реперфузионных повреждений конечности. Общая реаниматология 2006; II (5-6): 129-32).Miura T, Tanno M, Sato T . Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion induced necrosis. Cardiovasc. Res. 2010; 88 (1): 7-15.Miura T, Tanno M, Sato T . Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion induced necrosis. Cardiovasc. Res. 2010; 88 (1): 7-15.Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc. Drugs Ther. 2010; 24 (3): 225-34.Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc. Drugs Ther. 2010; 24 (3): 225-34.Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am. J. Cardiol. 1989; 63 (21): 18J-24J.Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am. J. Cardiol. 1989; 63 (21): 18J-24J.Malysheva AM, Martsevich SYu, Ginzburg ML. The use of nicorandil — a drug with additional cardioprotective properties in patients with coronary heart disease. Therapeutic archive 2011; 83, 9: 14-9. Russian (Малышева А. М., Марцевич С. Ю., Гинзбург М. Л. Применение никорандила — препарата с дополнительными кардиопротективными свойствами у пациентов с ишемической болезнью сердца. Терапевтический архив 2011; 83, 9: 14-9).Malysheva AM, Martsevich SYu, Ginzburg ML. The use of nicorandil — a drug with additional cardioprotective properties in patients with coronary heart disease. Therapeutic archive 2011; 83, 9: 14-9. Russian (Малышева А. М., Марцевич С. Ю., Гинзбург М. Л. Применение никорандила — препарата с дополнительными кардиопротективными свойствами у пациентов с ишемической болезнью сердца. Терапевтический архив 2011; 83, 9: 14-9).Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc. Drugs Ther. 1990; 4 (4): 1075-88.Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc. Drugs Ther. 1990; 4 (4): 1075-88.IONA Study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial. Lancet. 2002; 359 (9314): 1269-75.IONA Study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial. Lancet. 2002; 359 (9314): 1269-75.Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Aug 30. [Epub ahead of print].Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Aug 30. [Epub ahead of print].Gilyarovskiy SR, Rezvan VV, Kuzmina IM, et al. Modern approaches to anti-ischemic therapy in patients with stable coronary heart disease. Medical alphabet. Cardiology 2013. Russian (Гиляревский С. Р., Резван В. В., Кузьмина И. М. и др. Современные подходы к противоишемической терапии больных со стабильным течением ишемической болезни сердца. Медицинский алфавит. Кардиология 2013).Gilyarovskiy SR, Rezvan VV, Kuzmina IM, et al. Modern approaches to anti-ischemic therapy in patients with stable coronary heart disease. Medical alphabet. Cardiology 2013. Russian (Гиляревский С. Р., Резван В. В., Кузьмина И. М. и др. Современные подходы к противоишемической терапии больных со стабильным течением ишемической болезни сердца. Медицинский алфавит. Кардиология 2013).Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74:503-9.Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74:503-9.Martsevich SYu. Comparative evaluation of the antianginal efficacy and safety of the nicorandil with basic therapy with β-adrenoblockers in patients with coronary heart disease with stable angina. Cardiology, 2016: 30-4. Russian (Марцевич, С. Ю., Кутишенко Н. П., Деев А. Д. Сравнительная оценка антиангинальной эффективности и безопасности препарата никорандил на фоне базисной терапии β-адреноблокаторами у больных ишемической болезнью сердца со стабильной стенокардией. Кардиология, 2016; 30-4).Martsevich SYu. Comparative evaluation of the antianginal efficacy and safety of the nicorandil with basic therapy with β-adrenoblockers in patients with coronary heart disease with stable angina. Cardiology, 2016: 30-4. Russian (Марцевич, С. Ю., Кутишенко Н. П., Деев А. Д. Сравнительная оценка антиангинальной эффективности и безопасности препарата никорандил на фоне базисной терапии β-адреноблокаторами у больных ишемической болезнью сердца со стабильной стенокардией. Кардиология, 2016; 30-4).Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005 Aug 30; 112(9):1284-8.Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005 Aug 30; 112(9):1284-8.Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004 Oct;148(4):E15.Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004 Oct;148(4):E15.Ota S, Nishikawa H, Takeuchi M, et al. Impact of Nicorandil to Prevent Reperfusion Injury in Patients With Acute Myocardial Infarction Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006; 70: 1099-104.Ota S, Nishikawa H, Takeuchi M, et al. Impact of Nicorandil to Prevent Reperfusion Injury in Patients With Acute Myocardial Infarction Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006; 70: 1099-104.Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J. 2008 Sep; 72(9):1425-9.Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J. 2008 Sep; 72(9):1425-9.Kasama S, Toyama T, Sumino H, et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction J Nucl Med, 48 (2007): 1676-82.Kasama S, Toyama T, Sumino H, et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction J Nucl Med, 48 (2007): 1676-82.Sakata Y, Nakatani D, Shimizu M, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol. 2012 Jan;59(1):14-21. doi: 10.1016/j.jjcc.2011.08.001. Epub 2011 Sep 15.Sakata Y, Nakatani D, Shimizu M, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol. 2012 Jan;59(1):14-21. doi: 10.1016/j.jjcc.2011.08.001. Epub 2011 Sep 15.Yang J, Zhang J, Cui W, et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatolian J Cardiol 2015; 15: 125-31.Yang J, Zhang J, Cui W, et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatolian J Cardiol 2015; 15: 125-31.Izumiya Y, Kojima S, Kojima S, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011; 214:415-21.Izumiya Y, Kojima S, Kojima S, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011; 214:415-21.Kawai Y, Hisamatsu K, Matsubara H, et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 2009 Apr;30(7):765-72. doi: 10.1093/eurheartj/ehp077. Epub 2009 Mar 10.Kawai Y, Hisamatsu K, Matsubara H, et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 2009 Apr;30(7):765-72. doi: 10.1093/eurheartj/ehp077. Epub 2009 Mar 10.Isono T, Kamihata H, Sutani Y, et al. Nicorandil suppressed myocardial injury after percutaneous coronary intervention. Int J Cardiol. 2008 Jan 11;123(2):123-8. Epub 2007 Mar 8.Isono T, Kamihata H, Sutani Y, et al. Nicorandil suppressed myocardial injury after percutaneous coronary intervention. Int J Cardiol. 2008 Jan 11;123(2):123-8. Epub 2007 Mar 8.Hirohata A, Yamamoto K, Hirose E, et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pe ctoris: a randomised study. EuroIntervention.2014 Jan 22;9(9):1050-6. doi: 10.4244/EIJV9I9A178.Hirohata A, Yamamoto K, Hirose E, et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pe ctoris: a randomised study. EuroIntervention.2014 Jan 22;9(9):1050-6. doi: 10.4244/EIJV9I9A178.

The authors declare that there are no conflicts of interest present.